Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan L French

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Arthritis and Rheumatism|October 19, 2011
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate aloneJoel M Kremer, Stanley Cohen, Bethanie E Wilkinson, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 17, 2025
A Model-Based Meta-Analysis Framework Quantifying Drivers of Placebo Response in Atopic Dermatitis TrialsJean C Serrano, John Maringwa, Roel Straetemans, et al.
Journal of Crohn'S & Colitis|March 24, 2017
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's DiseaseMaria Rosario, Jonathan L French, Nathanael L Dirks, et al.
Journal of Crohn'S & Colitis|February 1, 2018
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's DiseaseMaria Rosario, Jonathan L French, Nathanael L Dirks, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Arthritis and Rheumatism|October 19, 2011
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate aloneJoel M Kremer, Stanley Cohen, Bethanie E Wilkinson, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 17, 2025
A Model-Based Meta-Analysis Framework Quantifying Drivers of Placebo Response in Atopic Dermatitis TrialsJean C Serrano, John Maringwa, Roel Straetemans, et al.
Journal of Crohn'S & Colitis|March 24, 2017
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's DiseaseMaria Rosario, Jonathan L French, Nathanael L Dirks, et al.
Journal of Crohn'S & Colitis|February 1, 2018
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's DiseaseMaria Rosario, Jonathan L French, Nathanael L Dirks, et al.
Pageof 2